The Thromboxane A 2 Receptor Antagonist S18886 Prevents Enhanced Atherogenesis Caused by Diabetes Mellitus | Zendy

Adriana Zuccollo | Zendy; Chaomei Shi | Zendy; Roberto Mastroianni | Zendy; Karlene A. Maitland-Toolan | Zendy; Robert M. Weisbrod | Zendy; Mengwei Zang | Zendy; Shanqin Xu | Zendy; Bingbing Jiang | Zendy; Jennifer OliverKrasinski | Zendy; Antonio J. Cayatte | Zendy; Stefano Corda | Zendy; Gilbert Lavielle | Zendy; Tony J. Verbeuren | Zendy; Richard A. Cohen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The Thromboxane A ₂ Receptor Antagonist S18886 Prevents Enhanced Atherogenesis Caused by Diabetes Mellitus

Author(s) -

Adriana Zuccollo,

Chaomei Shi,

Roberto Mastroianni,

Karlene A. Maitland-Toolan,

Robert M. Weisbrod,

Mengwei Zang,

Shanqin Xu,

Bingbing Jiang,

Jennifer OliverKrasinski,

Antonio J. Cayatte,

Stefano Corda,

Gilbert Lavielle,

Tony J. Verbeuren,

Richard A. Cohen

Publication year - 2005

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.105.581892

Subject(s) - medicine , endocrinology , diabetes mellitus , thromboxane , inflammation , thromboxane a2 , receptor antagonist , apolipoprotein e , endothelium , receptor , platelet , antagonist , disease

S18886 is an orally active thromboxane A2 (TXA2) receptor (TP) antagonist in clinical development for use in secondary prevention of thrombotic events in cardiovascular disease. We previously showed that S18886 inhibits atherosclerosis in apolipoprotein E-deficient (apoE(-/-)) mice by a mechanism independent of platelet-derived TXA2. Atherosclerosis is accelerated by diabetes and is associated with increased TXA(2) and other eicosanoids that stimulate TP. The purpose of this study was to determine whether S18886 lessens the enhanced atherogenesis in diabetic apoE(-/-) mice.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research